These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9001825)

  • 1. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine.
    Chiang G; Sassaroli M; Louie M; Chen H; Stecher VJ; Sperber K
    Clin Ther; 1996; 18(6):1080-92. PubMed ID: 9001825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes.
    Sperber K; Kalb TH; Stecher VJ; Banerjee R; Mayer L
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):91-8. PubMed ID: 8427717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.
    Sperber K; Chiang G; Chen H; Ross W; Chusid E; Gonchar M; Chow R; Liriano O
    Clin Ther; 1997; 19(5):913-23. PubMed ID: 9385480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-HIV-1 activity of chloroquine.
    Savarino A; Gennero L; Sperber K; Boelaert JR
    J Clin Virol; 2001 Feb; 20(3):131-5. PubMed ID: 11166661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of pregnancy steroid hormones and zidovudine in inhibition of HIV type 1 replication in monocytoid and placental Hofbauer cells: implications for the prevention of maternal-fetal transmission of HIV.
    Lee AW; Mitra D; Laurence J
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1235-42. PubMed ID: 9310291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1.
    Sperber K; Louie M; Kraus T; Proner J; Sapira E; Lin S; Stecher V; Mayer L
    Clin Ther; 1995; 17(4):622-36. PubMed ID: 8565026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells.
    Okamoto M; Ono M; Baba M
    AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1239-45. PubMed ID: 9764907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHI-05, a novel bromo-methoxy substituted phenyl phosphate derivative of zidovudine, is a dual-action spermicide with potent anti-HIV activity.
    D'Cruz OJ; Zhu Z; Yiv SH; Chen CL; Waurzyniak B; Uckun FM
    Contraception; 1999 May; 59(5):319-31. PubMed ID: 10494486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
    Piconi S; Parisotto S; Rizzardini G; Passerini S; Terzi R; Argenteri B; Meraviglia P; Capetti A; Biasin M; Trabattoni D; Clerici M
    Blood; 2011 Sep; 118(12):3263-72. PubMed ID: 21576701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).
    Yamaguchi K; Honda M; Ikigai H; Hara Y; Shimamura T
    Antiviral Res; 2002 Jan; 53(1):19-34. PubMed ID: 11684313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.
    Puertas MC; Buzón MJ; Artese A; Alcaro S; Menendez-Arias L; Perno CF; Clotet B; Ceccherini-Silberstein F; Martinez-Picado J
    J Virol; 2009 Aug; 83(15):7434-9. PubMed ID: 19457988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic effect of NMSO3 on replication of human immunodeficiency virus.
    Nakamura M; Terada M; Kamada M; Yokono A; Nakamori S; Ohno T
    Antivir Chem Chemother; 2003 Jul; 14(4):171-6. PubMed ID: 14582845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV replication and macrophage colony-stimulating factor production in human macrophages by antiretroviral agents.
    Kutza J; Fields K; Grimm TA; Clouse KA
    AIDS Res Hum Retroviruses; 2002 Jun; 18(9):619-25. PubMed ID: 12079557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
    Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M
    AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.